Biotherapies for Life
CSL Behring is a global biotherapeutics leader driven by our promise to save lives. We meet patients’ needs using the latest technologies to develop and deliver innovative therapies. The company offers the broadest range of products in the industry for treating coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. CSL Behring’s products are also used in cardiac surgery, organ transplantation, burn treatment and to prevent hemolytic disease of the newborn. The company operates one of the world’s largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL; USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 22,000 people, and delivers its life-saving therapies to people in more than 60 countries. For more information visit at CSLBehring.com/Vita and follow us on Twitter.com/CSLBehring.
"We do everything we do with passion - and we do it for life." (Stefan Drager, Executive Board Chairman)
As an international leader in medical and safety technology, Drager develops innovative equipment and solutions that people all over the world over trust when lives are on the line. Our medical division's product range covers anesthesia workstations, ventilation equipment for intensive care, emergency, neonatal and mobile ventilation units, warming therapy equipment for infants, patient monitoring equipment, IT solutions, architectural systems and gas management systems.
Edwards Lifesciences has been advancing the care of the acutely ill for over 40 years. We are focused on helping clinicians enhance knowledge and standardize practice to improve the quality and efficiency of care. Edwards is dedicated to providing evidence-based medicine programs such as the Enhanced Surgical Recovery Program that facilitates the implementation and compliance of protocolized care in the OR in order to reduce post-surgical complications. Edwards also offers a range of advanced monitoring tools – including noninvasive to minimally-invasive hemodynamic monitoring and continuous glucose monitoring – expansive educational resources, and clinical support to ensure sustained compliance.
Fresenius Medical Care (FME) offers services & products in more than 120 countries and cares for more than 310,000 patients in our global network of more than 3,600 dialysis clinics. At the same time, we operate 37 production sites on all continents, to provide dialysis products such as dialysis machines, dialyzers and related disposables.
Offering a variety of therapies, Fresenius Medical Care provides efficient treatment of acute kidney injury to fit each patient's specific needs. Besides the several options for CRRT, Fresenius Medical Care also provides options for plasmapheresis and therapeutic apheresis.
Therapeutic apheresis is a therapy for removing pathogenic substances from blood using filters and adsorbers. With a portfolio of different adsorbers and long-standing expertise in extracorporeal procedures, Fresenius Medical Care delivers a combination of quality and flexible treatment alternatives, designed to treat a wide range of diseases and increase the patient’s quality of life.
In January 2017, Fresenius Medical Care acquired the Xenios company. Xenios offers minimally invasive disposable lung and heart therapies on one single platform. This acquisition is an opportunity to expand FME’s position as the global leader in extracorporeal organ support.
Getinge AB is a Sweden-based company active in the healthcare sector. It provides products and services for intensive care units, sterilization centers, elderly care and companies and institutions active in the life sciences area. Its operations are divided into three business areas: The Medical Systems business area offers equipment for surgical disciplines, cardiology and intensive care; the Extended Care business area offers products and services geared toward the hospital and elderly care markets, including solutions for preventing the risk of pressure ulcers and deep vein thrombosis, and the Infection Control business area features systems for preventing the occurrence and spread of infection. Its products comprise disinfectors, sterilizers, including low temperature sterilization solutions, information technology (IT) solutions, as well as advice, training and technical support. The Company's products are sold under the Getinge, Lancer, ArjoHuntleigh and MAQUET brands.
Maquet, a trusted partner for hospitals and physicians for more than 175 years, is a global leader in medical systems. The company offers innovative therapy solutions and infraY structure capabilities for highYacuity areas within the hospital Y including the operating room, hybrid OR, and intensive care unit Y as well as intraY and interYhospital patient transport. Additionally, Maquet develops intelligent and sustainable room concepts that exceed the expectations of modern hospitals, working in close cooperation with customers, production engineers and architects to integrate high quality products and services. Headquartered in Rastatt, Germany, Maquet is the largest subsidiary of the publicly listed Getinge Group AB of Sweden. Maquet generated about 1.55 billion Euros in 2014, representing more than half of the Getinge Group’s annual revenue of 2.93 billion Euros. Maquet has around 7,000 employees and provides 53 international sales and service organizations. Maquet is The Gold Standard. For more information, please visit www.maquet.com.
Masimo (NASDAQ: MASI) is a global medical technology company that develops and manufactures innovative noninvasive patient monitoring technologies, including medical devices and a wide array of sensors. A key medical technology innovator, Masimo is responsible for the invention of award-winning noninvasive technologies that are revolutionizing patient monitoring, including Masimo SET® pulse oximetry, Masimo Rainbow Pulse CO-Oximetry and new Masimo noninvasive and continuous total hemoglobin (SpHb™) monitoring technology. The recent introduction of the first-and-only FDA-cleared technology that noninvasively and continuously measures total hemoglobin without a painful needle stick and invasive blood draw is expected to open new markets and significantly expand the company’s growth opportunities.
Founded more than 20 years ago in Munich Germany, Pulsion has become a leading specialist in haemodynamic monitoring and provides the clinician with a variety of technologies to optimise the haemodynamic management of patients in ICU and in the OR; transpulmonary thermodilution technique for cardiac output, preload and lung water measurements (PiCCO); fibreoptic continuous measurement of the central venous oxygen saturation via standard CVC (CeVOX); non-invasive evaluation of the liver function and splanchnic perfusion with indocyanine green dye (LiMON); non-calibrated CO trend measurement via standard arterial line (ProAQT); and the PulsioFlex monitoring platform with the modular concept to enable patient centred flexibility.